Introduction: In a tribal population based area in West Bengal, India though carcinoma cervix is the commonest malignancy in female patients, yet apart from that carcinoma breast is also increasing in number in the recent years. Breast cancer accounts for approximately 26.6% of female malignancy in the radiation oncology out-patient-department of our teaching hospital. Aims and Objectives: To compare conventional RT regimen (50 Gy in 25 fractions over 5 weeks) with one hypofractionated regimen (40Gy in 15 fractions over 3 weeks) in stage II & stage III breast cancer patients as adjuvant radiation therapy in terms of local control, survival and adverse reactions.
INTRODUCTION
As we are aware of the fact that radiotherapy is a mandatory modality in the course of treatment for Carcinoma of Breast, various dose prescriptions aside the conventional one had also been tried in particularly adjuvant setting [1] . The goal was to find out an optimum dose prescription by dint of which adequate local control could be achieved respecting the acute and late toxicities. Though breast cancer awareness programs and thorough screening have succeeded enough in developed countries in terms of early diagnosis, in developing countries like India diagnosis at an early stage and early commencement of treatment remain still a challenge [2] . Our practice domain includes a rural-based area i.e. Bankura in West Bengal, India where carcinoma cervix is still the commonest malignancy followed by ca breast as the second commonest malignant entity in the female population. But according to the records of recent years preserved by the Department of Radiation Oncology of Bankura Sammilani Medical College & Hospital, an increase in the incidence of breast cancer is a burning fact. Currently, breast cancer accounts for 26.6% of female malignancies in this area, as recorded, majority of which presented as Locally Advanced Breast Cancer (LABC), with AJCC stage T2 -4, any N. As recommended, multidisciplinary approach including neoadjuvant chemotherapy (NACT), surgery, adjuvant radiotherapy, adjuvant chemotherapy, hormonal therapy and immunotherapy form the lines of treatment considering all patient factors, disease factors and treatment factors.
Modified radical mastectomy (MRM) dominates over Breast Conservation Surgery (BCS) with a statistic of 97.74% vs. 2.26% [3] . Due to the belief that removal of the entire diseased breast is mandatory to cure cancer they always opted for MRM even in those favourable cases where BCS might be a better option in term of cosmesis. However our study dealt with adjuvant radiotherapy, which was aimed to compare the so-called conventional breast RT regimen (50 Gy in 25 fractions over 5 weeks) with one hypofractionated regimen (40Gy in 15 fractions over 3 weeks) in stage II & stage III breast cancer patients as adjuvant therapy in terms of local control, survival and adverse reactions.
MATERIALS AND METHODS

Patients and Methods
In this single institutional retrospective study total 302 consecutive patients who got registered between May 2012 and April, 2017 in the outpatient department of Radiotherapy in BSMC(Bankura Sammilani medical college and Hospital) were included. Out of which thirty six patients failed to follow up; so total 266 patients were included in the study finally. After clinical evaluation including local and locoregional examination of bilateral breast and axillae a complete mammogram with proper BIRADS scoring was done. It was followed by a tru-cut biopsy confirming the pathological diagnosis of invasive breast cancer. As fine needle aspiration cytology sample does not suffice to perform immunohistochemistry, tru-cut biopsy was a mandatory inclusion criteria. It was followed by immunohistochemistry stating the oestrogen and progesterone receptor status and HER2 neu amplification status too. Ki 67 was not routinely done in our public hospital before 2014, hence Modified Nottingham Prognostic Index (NPI) Scoring was considered significant to determine the grade of aggressiveness of the infiltrative carcinoma. It was followed by complete metastatic workup including a digital chest X ray sometimes an additional Contrast Enhanced Computed Tomography (CECT) Scan of Thorax, a CECT Scan of the whole abdomen. A Magnetic Resonance Imaging of brain was performed in symptomatic patients with the suspicion of brain metastasis. Patients who were clinical, AJCC anatomic prognostic stage group IIA, IIB, IIIA, IIIB and IIIC were included. Simply, T-stages included were T2-T4 and N-staged included were N0-N3. Significant baseline characteristics used for 1:1 patient matching included history regarding age (<50 years vs. >50 years; no more than 3 years apart), menopausal status (premenopausal vs. postmenopausal), number of relatives affected (1st degree vs. 2nd degree vs. no family history). BRCA 1 and BRCA 2 mutation analysis was not routinely done in our institution. Disease-related factors for patient matching were T-stage, N-stage, AJCC Prognostic stage group, NPI Score, status of post-surgery histopathological examination (HPE) report, ypT and ypN status as patients received Neo Adjuvant Chemotherapy regimens, Hormonal Receptor status, Her-2neu status etc. Other minor factors like age at first child birth (no more than 2 years apart), duration of breastfeeding (obtained from parity), the month that patients received the treatment in question i.e. radiation therapy (no more than 6 months apart) were attempted to match afterwards. 
Treatment Protocol
Response Assessment
After completion of radiation therapy, clinical examination of bilateral breasts and axilla and high-resolution ultrasonography of ipsilateral chest flap, contralateral breast and bilateral axillae was done after 2 months. A chest X-ray and a CECT whole abdomen was done 3 monthly. MRI brain was performed on the basis of presenting symptoms as and when required. RECIST v1.1 criteria was used to determine complete response (CR), progressive disease (PD), partial response (PR) or stable disease (SD) in consequent follow ups after completion of treatment. Radiation toxicities (both acute and late) were assessed using RTOG (Radiation Therapy Oncology Group) toxicity grading. Median disease-free survival (DFS) or progression-free survival (mPFS) and overall survival (OS) were analysed using KaplanMeier survival over a median follow up of 60 months.
Statistical Analysis
SPSS statistical software version 17 (IBM Corp., Chicago, IL, USA) was used for data analysis. Quantitative data were presented by mean or median as appropriate, and qualitative data were presented as a percentage. OS and PFS/DFS were analysed by the Kaplan-Meier method and compared between both groups by log rank test (p= 0.05). The Cox proportional hazards model was used to adjust all prognostic factors. A 2-sided p-value <0.05 was considered statistically significant.
RESULTS
In this rural population-based retrospective study a total number of patients included was three hundred two (302). Thirty six patients (36) failed to follow up. Hence, finally two hundred sixty six patients (266) were evaluated for this study (n = 266). They have been divided into two groups namely A & B. each containing 133 patients (n 133). 1:1 patient matching was done considering the criteria mentioned previously. In Group A conventional fractionation radiation therapy (CFRT) i.e. 50Gy in 25 fractions over 5 Table 3) .
So on the basis of OS, DFS & locoregional recurrence, there are no statistically significant differences lies between the two Groups. Fig. 1 shows a graphical representation of the probability of subclinical breast tumour control and normal tissue toxicity with increasing dose in Gy. Between 1998 and 2002, 2236 women with early breast cancer (pT1-3a pN0-1 M0) at 17 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2·0 Gy versus 41·6 Gy or 39 Gy in 13 fractions of 3·2 Gy or 3·0 Gy over 5 weeks. 749 women were assigned to the 50 Gy group, 750 to the 41·6 Gy group, and 737 to the 39 Gy group. After a median follow up of 5·1 years (IQR 4·4-6·0) the rate of local-regional tumour relapse at 5 years was 3·6% (95% CI 2·2-5·1) after 50 Gy, 3·5% (95% CI 2·1-4·3) after 41·6 Gy, and 5·2% (95% CI 3·5-6·9) after39 Gy. The estimated absolute differences in 5-year local-regional relapse rates compared with 50 Gy were 0·2% (95% CI −1·3% to 2·6%) after 41·6 Gy and 0·9% (95% CI −0·8% to 3·7%) after 39 Gy. Photographic and patient self-assessments suggested lower rates of late adverse effects after 39 Gy than with 50 Gy, with an HR for the late change in breast appearance (photographic) of 0·69 (95% CI 0·52-0·91, p=0·01). The study concluded the data are consistent with the hypothesis that breast cancer and the dose-limiting normal tissues respond to cancer and the dose-limiting normal tissues respond similarly to change in radiotherapy fraction size. 41·6 Gy in 13 fractions was similar to the control regimen of 50 Gy in 25 fractions in terms of local-regional tumour control [5] .
Study conducted to test the benefits of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy. 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 week. 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of localregional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)--ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy. The study interpreted 1105 women were assigned to the 50 Gy group and 1110 to the 40 were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)--ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy [6] .
Owen JR in his randomized trial, tested whether fewer, larger fractions were at least as safe and as effective as standard regimens. In this analysis, also assessed the long-term results of tumour control in the same population. In this study 1410 women with invasive breast cancer (tumour stage 1-3 with a maximum of one positive node and no metastasis) who had had local tumour excision of early-stage breast cancer were randomly assigned to receive 50 Gy radiotherapy given in 25 fractions, 39 Gy given in 13 fractions, or 42.9 Gy given in 13 fractions, all given over 5 weeks. The primary endpoint was a late change in breast appearance, which has been reported elsewhere. 1410 women with invasive breast cancer (tumour stage 1-3 with a maximum of one positive node and no metastasis) who had had local tumour excision of no metastasis) who had had local tumour excision of early stage breast cancer to receive 50 Gy radiotherapy given in 25 fractions, 39 Gy given in 13 fractions, or 42.9 Gy given in 13 fractions, all given over 5 weeks. The primary endpoint was late change in breast appearance, which has been reported elsewhere. The study concluded Breast cancer tissue is probably just as sensitive to fraction size as dose-limiting healthy tissues [7] .
Yarnold et al. [8] Sanz [9] conducted a study to analyze the results of weekly hypofractionated treatment in 486 elderly patients with associated diseases that modify their performance status and do not tolerate long periods of daily irradiation. They were treated with conservative surgery or mastectomy and then adjuvant hypofractionated irradiation, administering 5 Gy or 6.25 Gy in 6 fractions, once a week (total dose 30-37.5 Gy) over 6 weeks. The study concluded once-weekly hypo-fractionated radiotherapy is a feasible and convenient option for elderly patients with breast cancer. It is a safe treatment modality with similar survival and local control results compared to standard fractionation, while the side effects are acceptable [9] Sun et al. [10] and Team conducted a phase III noninferior randomized trial to evaluate the efficacy and toxicity of HFRT after mastectomy. In this analysis, 820 high-risk patients mainly with stage III breast cancer were enrolled and followed up for 5 years. Patients were randomly assigned after mastectomy to receive either HFRT (43.5 Gy/15f/3w) or CFRT (50 Gy/25f/5w) to the chest wall and supraclavicular nodal region. The primary endpoint was loco-regional recurrence (LRR women, two studies) was reduced with altered fraction size. Altered fraction size was associated with less patient-reported (P < 0.001) and physician-reported (P = 0.009) fatigue at six months (287 women, one study). The review concluded altered fraction size regimens (greater than 2 Gy per fraction) does not have a clinically meaningful effect on local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance, late toxicity or patient-reported quality-of-life measures for selected women treated with breast conserving therapy [11] .
The randomized trial was from the MD Anderson Cancer Center, in Houston. The study was conducted in 287 women aged 40 years and older with early-stage breast cancer (stage 0-2), who were randomly assigned to receive either HF-WBI (42.56 Gy in 16 fractions of WBI; n = 138) or CF-WBI (50.00 Gy in 25 fractions of WBI; n = 149). The rate of physician-assessed toxicity of grade 2 or higher was significantly lower for women receiving HF-WBI (47% vs 78%; P < .001), as were acute toxic effects of grade 3 of higher 001), as were acute toxic effects of grade 3 of higher (0% vs 5%; P = .01). In particular, rates for physician-assessed fatigue, pruritus, breast pain, and dermatitis were significantly lower for women receiving HF. Although patient-reported quality of life, as reported from the Functional Assessment of Cancer Therapy for Patients with Breast Cancer, was similar for women receiving HF and CF, items associated with lack of energy and trouble meeting family needs favoured women receiving HF. The study concluded treatment with HF-WBI appears to yield lower rates of acute toxic effects than CF-WBI as well as less fatigue and less trouble meeting family needs 6 months after completing radiation therapy [12] .
A task force authorized by the American Society for Radiation Oncology weighed evidence from a systematic literature review and produced the recommendations contained herein. The majority of patients in randomized trials were aged 50 years or older, had disease Stage pT1-2 pN0, did not receive chemotherapy, and were treated with a radiation dose homogeneity within ±7% in the central axis plane. Such patients experienced equivalent outcomes with either HF-WBI or CF-WBI. Patients not meeting these criteria were relatively underrepresented, and few of the trials reported subgroup analyses. For patients not receiving a radiation boost, the task force favoured a dose schedule of 42.5 Gy in 16 fractions when HF-WBI is planned. The task force also recommended that the heart should be excluded from the primary treatment fields (when HF-WBI is used) due to lingering uncertainty regarding late effects of HF-WBI on cardiac function. Data were sufficient to support the use of HF-WBI for patients with early-stage breast cancer who met all the aforementioned criteria. For other patients, the task force could not reach agreement either for or against the use of HF-WBI, which nevertheless should not be interpreted as a contraindication to its use [13] .
Chan et al. [14] 18 .9%-23.6%) in 2013 in the hypofractionation-permitted cohort. Adjusted mean total health care expenditures in the 1 year after mean total health care expenditures in the 1 year after diagnosis were $28,747 for hypofractionated and $31,641 for conventional WBI in the hypofractionation-endorsed cohort (difference, $2894; 95% CI, $1610-$4234; P < .001) and $64,273 for hypofractionated and $72,860 for conventional WBI in the hypofractionation-permitted cohort (difference, $8587; 95% CI, $5316-$12,017; P < .001). Adjusted mean total 1-year patient out-of-pocket expenses were not significantly different between hypofractionated vs conventional WBI in either cohort [17] .
Deshmukh et al.
[18] constructed a decisionanalytic model that followed women who were treated with lumpectomy for early-stage breast cancer. Recurrence, mortality, complication rates, and utilities (five-year radiation-associated quality of life scores), were extracted from RCTs. Costs were based on Medicare reimbursement rates. HF-WBI dominated CF-WBI (ie, resulted in higher quality-adjusted life-years [QALYs] and lower cost) in all scenarios. HF-WBI also had a greater likelihood of cost-effectiveness compared with IORT; under a societal perspective that assumes that radiationassociated disutility persists, HF-WBI results in an ICER of $17 024 per QALY compared with IORT with a probability of cost-effectiveness of 80% at the $100 000 per QALY willingness-topay of 80% at the $100 000 per QALY willingness-to-pay threshold. If radiationassociated disutility is assumed to discontinue, the ICER is lower ($11 461/QALY), resulting in an even higher (83%) probability of relative costeffectiveness. The ICER was most sensitive to the probability of metastasis and treatment cost. The study concluded, for women with earlystage breast cancer requiring adjuvant radiotherapy, HF-WBI is cost-effective compared with CF-WBI and IORT [18] .
The result of our study clearly suggests that outcome for both dose schedule was equivalent. Hypofractionation is rather cost effective considering the low socio-economic status of our practice domain which reflects a major population of India.
CONCLUSION
There is no significant difference in between the conventional regimen and this hypofractionated regimen in terms of OS, DFS and adverse reactions. Hence, in our institution, we usually prefer Hypofractionated radiotherapy (40Gy/15 fractions) in adjuvant settings for breast cancer patients.
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